FA
ALXO icon

Forefront Analytics’s ALX Oncology ALXO Stock Holding History

Forefront Analytics’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,261
Closed -$114K – 69
2024
Q1 		$114K Buy
+10,261
New +$144K 0.06% 59
2023
Q4 		– Sell
-13,769
Closed -$66.1K – 68
2023
Q3 		$66.1K Buy
+13,769
New +$74.7K 0.04% 60
2023
Q2 		– Sell
-13,037
Closed -$58.9K – 67
2023
Q1 		$58.9K Buy
+13,037
New +$98.8K 0.03% 68

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Forefront Analytics's ALXO Position: Q2 2024 in Review

Forefront Analytics sold out of ALX Oncology (ALXO) in Q2 2024, closing a stake of 10,261 shares — an estimated $114K sold.

Forefront Analytics first reported a position in ALXO in Q1 2023 and held it in 3 quarters. The position peaked at $114K in Q1 2024. 111 funds tracked by Wall St. Rank hold ALXO as of Q2 2024.

  • Forefront Analytics reported no remaining ALX Oncology position as of Q2 2024 after selling out during the quarter.
  • Forefront Analytics sold 10,261 ALX Oncology shares in Q2 2024, an estimated $114K.
  • Forefront Analytics first reported a position in ALX Oncology in Q1 2023 and held it in 3 quarters.
  • Forefront Analytics's ALX Oncology position peaked at $114K in Q1 2024.
  • 111 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2024.

Based on Forefront Analytics's 13F filing for Q2 2024, filed 15 Aug 2024.